Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

Pfizer said on Thursday it will end global development of its hemophilia gene therapy, Beqvez, citing soft demand from ...

Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec ...

Pfizer may appeal to income investors, but growth prospects remain uncertain. Read why PFE stock might struggle to gain ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

An archived Facebook post claimed that Pfizer has released a list of side effects for COVID vaccine. The claim by the user is ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and commercialization of its hemophilia B gene therapy, Beqvez. In April 2024, the FDA ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...